Therapeutic antibodies have come of age with major progress being made in cancer, autoimmunity and chronic inflammation, as well as a wide range of other human diseases. Antibody engineering is further driving development of novel antibody formats and genetically modified cell-based therapies that harness the power of the immune system to progress cures in otherwise intractable human diseases. Nevertheless, there are still significant challenges ahead for basic and applied research relating to therapeutic antibodies. This special issue of the journal provides reviews and opinions that relate to the discovery, design and deployment of antibodies as therapeutics
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments fo...
Antibodies have been used therapeutically to treat a variety of clinical conditions. The introductio...
Since their discovery, antibodies have been viewed as ideal candidates or "magic bullets" for use in...
Therapeutic monoclonal antibodies have become an important class of modern medicines. The establishe...
Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. Th...
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments fo...
Immunotherapy has been well regarded as one of the safer and antigen-specific anti-cancer treatments...
Antibody-based therapeutics currently enjoy unprecedented success, growth in research and revenues, ...
Antibody-based therapeutics currently enjoy unprecedented success, growth in research and revenues, ...
International audienceThe dawn of the 20th century saw the formative years of developments in immuno...
International audienceThe dawn of the 20th century saw the formative years of developments in immuno...
Special Issue addresses fundamental issues and advances in our field. Contributions from the partici...
Special Issue addresses fundamental issues and advances in our field. Contributions from the partici...
ABSTRACT As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority...
Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the tr...
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments fo...
Antibodies have been used therapeutically to treat a variety of clinical conditions. The introductio...
Since their discovery, antibodies have been viewed as ideal candidates or "magic bullets" for use in...
Therapeutic monoclonal antibodies have become an important class of modern medicines. The establishe...
Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. Th...
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments fo...
Immunotherapy has been well regarded as one of the safer and antigen-specific anti-cancer treatments...
Antibody-based therapeutics currently enjoy unprecedented success, growth in research and revenues, ...
Antibody-based therapeutics currently enjoy unprecedented success, growth in research and revenues, ...
International audienceThe dawn of the 20th century saw the formative years of developments in immuno...
International audienceThe dawn of the 20th century saw the formative years of developments in immuno...
Special Issue addresses fundamental issues and advances in our field. Contributions from the partici...
Special Issue addresses fundamental issues and advances in our field. Contributions from the partici...
ABSTRACT As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority...
Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the tr...
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments fo...
Antibodies have been used therapeutically to treat a variety of clinical conditions. The introductio...
Since their discovery, antibodies have been viewed as ideal candidates or "magic bullets" for use in...